Overland Park: Shift Pharmaceuticals is pleased to announce the Company has been awarded a grant through the Congressional Directed Medical Research Program (CDMRP) to further the development of their initial drug candidate (E1v1.11) for the treatment of Spinal Muscular Atrophy ($2.7M). “This funding will allow the Company to move our lead candidate forward towards IND filing and clinical trials”, said Steve O’Connor, CEO of Shift Pharmaceuticals.


Columbia, MO – Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders. Our first candidate (E1v1.11) targets patients born with Spinal Muscular Atrophy (SMA). SMA occurs in 1:11,000 live births with devastating effects, often proving fatal for most patients under the age of 2. SMA is the leading genetic cause of infantile death worldwide and is marked by severe neurodegeneration and skeletal muscle wasting. Shift was co-founded by serial entrepreneur Dr. Steve O’Connor and world leading SMA research expert Dr. Chris Lorson. The company has licensed the core intellectual property from The University of Missouri, where the initial discovery and development was performed by Dr. Lorson. For more information, visit www.shiftpharmaceuticals.com.


The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702- 5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-18-1-0165. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture.